iShares Morningstar Mid-Cap Value ETF (NASDAQ: IMCV)

iShares Morningstar Mid-Cap Value ETF (NASDAQ:IMCV), Quote.Headers.trade-ideas

Financial Services

Utilities

Technology

Industrials

Consumer Cyclical

Healthcare

Real Estate

Consumer Defensive

Basic Materials

Energy

Communication Services

Other

The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index measures the performance of stocks issued by mid-capitalization companies that have exhibited value characteristics as determined by Morningstar, Inc.s (Morningstar or the index provider) proprietary index methodology.

Truist Financial Corp.

Norfolk Southern Corp.

Dr Horton Inc.

Valero Energy Corp.

American International Gr

Williams Cos. Inc.

American Electric Power Co. Inc.

Paccar Inc.

General Motors Co.

iShares Morningstar Mid-Cap Value ETF

Loop Capital analyst Jeffrey Stevenson maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Buy and raises the price target from $190 to $230.

News

Price Target

Analyst Ratings

BLDR

Loop Capital Maintains Buy on Builders FirstSource, Raises Price Target to $230

WIIM

APLS

Apellis Pharmaceuticals shares are trading lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency has confirmed its June 2024 negative opinion on the company's intravitreal pepcetacoplan for geographic atrophy secondary to age-related macular degeneration.

Cardinal Health To Acquire Integrated Oncology Network For $1.115B, Expanding Navista Alliance With Over 100 Providers Across 50 Community-Based Sites In 10 States

Editor&#8217;s Note: The article has been updated to reflect the correct company, Viking Holdings Ltd.
On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Viking Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>). &#8220;This is a really fine company, and it will do well for multiple years because they have many <a href="https://www.benzinga.com/quote/VKTX/news">ships coming in,&#8221; he added.</a>
On Sept. 11, JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65.
Gentex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) is &#8220;too closely related to autos, and autos have been hurt so bad. And I don't see a quick turn. We're going to need several Fed rate cuts before they turn,&#8221; Cramer said.
On July 26, the company reported second-quarter earnings per share of 37 cents, but it missed the street view of 52 cents. Quarterly sales of $572.93 million missed the analyst consensus of $622.79 million.
The Mad Money host said Cadre Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDRE#NYSE">CDRE</a>) is a &#8220;good simple story.&#8221;
On Aug. 9, Cadre Hldgs reported quarterly earnings of 31 cents per share which beat the analyst consensus estimate of 27 cents per share. The company reported quarterly sales of $144.31 million which beat the analyst consensus estimate of $142.05 million.
&#8220;Something's the matter with Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>),&#8221; Cramer said. &#8220;I want to know what's wrong.&#8221;
On Sept. 19, Celsius Holdings appointed Hans Melotte to the company&#8217;s Board of Directors.
Price Action:
<ul>
<li>Viking shares gained 5.8% to settle at $68.16 on Thursday.</li>
<li>Gentex shares gained 1.8% to close at $29.82 during the session.</li>
<li>Cadre shares gained 2.4% to close at $37.36 during Thursday's session.</li>
<li>Celsius shares fell 0.6% to settle at $34.07 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40948972/coinbase-global-electronic-arts-and-2-other-stocks-executives-are-selling">Coinbase Global, Electronic Arts And 2 Other Stocks Executives Are Selling</a></li>
</ul>

Long Ideas

Markets

Media

Trading Ideas

CDRE

CELH

GNTX

Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In' (CORRECTED)

Friday, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS).
The <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-20-09-30-00-2949552" rel="noreferrer noopener">data</a> demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.69; p=0.0026).
Further analysis of secondary endpoints demonstrated that the number of participants who experienced confirmed disability improvement increased by nearly two-fold, 10% with tolebrutinib compared to 5% with placebo (HR 1.88; nominal p=0.021).
Based on the preliminary analysis of the HERCULES study, there was a slight increase in tolebrutinib-treated patients of some adverse events.
Liver enzyme elevations were observed in 4.1% of participants receiving tolebrutinib compared with 1.6% in the placebo group, a side effect also reported with other BTK inhibitors in MS.
All but one case of liver enzyme elevations were resolved without further medical intervention.
Earlier this month, Sanofi released results from the GEMINI 1 and 2 phase 3 studies of tolebrutinib that did not meet the primary endpoint of reducing annualized relapse rate (ARR) compared to Aubagio (teriflunomide) in relapsing <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40684403/sanofi-still-bets-on-multiple-sclerosis-med-tolebrutinib-despite-the-investigational-drug-fell-sh" rel="noreferrer noopener">forms of multiple sclerosis</a>.
However, analysis of the key secondary endpoint of pooled 6-month confirmed disability worsening (CDW) data showed a considerable delay in time to onset, which supports the CDP data observed in HERCULES.
In preliminary analysis of the GEMINI 1 and 2 pooled safety data, adverse events observed between the tolebrutinib and Aubagio arms were generally balanced. Liver enzyme elevations were observed in 5.6% of participants receiving tolebrutinib compared with 6.3% of participants receiving Aubagio.
Study results will form the basis for future discussions with global regulatory authorities, with submissions starting in H2 2024.
The PERSEUS phase 3 study in primary progressive MS is ongoing, with study results anticipated in H2 2025.
Price Action: SNY stock is down 0.53% at $57.95 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40956171/european-drug-agency-supports-novo-nordisks-blockbuster-weight-loss-drug-wegovy-for-obesity-relat" target="_blank" rel="noreferrer noopener">European Drug Agency Supports Novo Nordisk&#8217;s Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure</a>.</li>
</ul>
Image by HJBC via Shutterstock

Biotech

Large Cap

Health Care

General

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows

Jeff Bezos, Oprah Winfrey and Sandra Bullock top the list of celebrities with the highest number of properties in the U.S., each owning seven properties.
An analysis by real estate investment company SoCal homebuyers reveals that celebrity real estate portfolios are reaching new heights amid a growing trend of wealth diversification through property ownership.
Don't Miss:
<ul>
<li>Elon Musk&#8217;s secret mansion in Austin revealed through court filings.<a href="https://www.benzinga.com/money/elon-musk-secret-mansion-austin-nada"> Here&#8217;s how to invest in the city&#8217;s growth before prices go back up.</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>
In terms of value, SoCal homebuyers found that Bezos's portfolio is worth the most at $458.9 million, followed by Jay-Z and Beyoncé, who own five properties worth a total of $315.5 million.
"These <a href="https://www.benzinga.com/real-estate/24/09/40901909/j-los-home-hunt-a-surprising-twist-as-she-considers-property-neighboring-ex-boyfriend-diddy-combs">celebrity portfolios</a> offer valuable lessons for all investors," SoCal homebuyers Co-Founder Doug Van Soest said. "While the scale is impressive, the underlying principles are universal. Diversification, location selection and long-term value appreciation are key, whether you're investing millions or starting with a single property."
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
<h2 class="wp-block-heading">10 Celebrities With Highest Number Of Properties In U.S.</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Rank</td>
<td>Celebrity</td>
<td>Number of properties</td>
</tr>
<tr>
<td>1</td>
<td>Jeff Bezos</td>
<td>7</td>
</tr>
<tr>
<td>1</td>
<td>Oprah Winfrey</td>
<td>7</td>
</tr>
<tr>
<td>1</td>
<td>Sandra Bullock</td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>Leonardo DiCaprio</td>
<td>6</td>
</tr>
<tr>
<td>4</td>
<td>Taylor Swift</td>
<td>6</td>
</tr>
<tr>
<td>6</td>
<td>George Lucas</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>Jay-Z and Beyoncé</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>Kim Kardashian</td>
<td>5</td>
</tr>
<tr>
<td>9</td>
<td>Kylie Jenner</td>
<td>4</td>
</tr>
<tr>
<td>9</td>
<td>Reese Witherspoon</td>
<td>4</td>
</tr>
</tbody>
</table>
</figure>
Source: SoCal homebuyers
Bezos's portfolio includes a $165 million estate in Beverly Hills, California and a $78 million Hawaii resident property, reflecting his penchant for luxury and privacy. The Beverly Hills mansion, formerly owned by media mogul David Geffen, is on nine acres and boasts multiple buildings, a tennis court and a nine-hole golf course.
Trending: Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a>
<a href="https://www.benzinga.com/real-estate/24/07/40001374/from-bill-gates-to-oprah-winfrey-the-most-lavish-celebrity-homes-revealed">Winfrey</a>'s real estate investments range from a sprawling 66-acre estate in Montecito, California, to a ski home in Telluride, Colorado. Her California property, dubbed The Promised Land, features a 23,000-square-foot main house with many luxurious amenities. The Telluride ski house, valued at $14 million, offers mountain views and unique features like a 56-foot-long wine cellar.
Bullock's diverse real estate portfolio includes homes in New Orleans, Southern California and Austin, Texas. Her $2.7 million Victorian home in the Big Easy's Garden District showcases classic architectural details, while her lakefront home in Austin boasts modern design. Her Beverly Hills residence offers privacy in an exclusive gated community.
Trending: Oprah, Madonna and DiCaprio have turned to the alternative asset that is outperforming the S&amp;P 500<a href="https://www.benzinga.com/money/masterworks">. Discover the potential of this market before other investors.</a>
<h2 class="wp-block-heading">10 Celebrities With Highest-Value Property Portfolio In U.S.</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Rank</td>
<td>Celebrity</td>
<td>Total value paid for properties</td>
</tr>
<tr>
<td>1</td>
<td>Jeff Bezos</td>
<td>$458,900,000</td>
</tr>
<tr>
<td>2</td>
<td>Jay-Z and Beyoncé</td>
<td>$315,450,000</td>
</tr>
<tr>
<td>3</td>
<td>George Lucas</td>
<td>$196,100,000</td>
</tr>
<tr>
<td>4</td>
<td>Mark Zuckerberg</td>
<td>$166,000,000</td>
</tr>
<tr>
<td>5</td>
<td>Kim Kardashian</td>
<td>$115,100,000</td>
</tr>
<tr>
<td>6</td>
<td>Taylor Swift</td>
<td>$92,750,000</td>
</tr>
<tr>
<td>7</td>
<td>Ellen DeGeneres</td>
<td>$91,500,000</td>
</tr>
<tr>
<td>8</td>
<td>Oprah Winfrey</td>
<td>$84,415,000</td>
</tr>
<tr>
<td>9</td>
<td>Kylie Jenner</td>
<td>$66,750,000</td>
</tr>
<tr>
<td>10</td>
<td>Madonna</td>
<td>$61,300,000</td>
</tr>
</tbody>
</table>
</figure>
Source: SoCal homebuyers
"In our experience, successful real estate investment is about more than status – it's about making informed decisions based on market trends and potential for growth," Van Soest said. "Even in today's dynamic market, real estate remains a powerful tool for building and preserving wealth when approached strategically."
Read Next:
<ul>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Celebrity Property Portfolios Soar, With Bezos And Oprah Tied For The Top Spot

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40954941/palantir-expands-maven-smart-system-aiml-capabilities-to-military-services" rel="noreferrer noopener">trading lower in the premarket session on Friday.</a>
The company announced a contract granted by the DEVCOM Army Research Laboratory (ARL) that broadens Maven Smart System access across military branches, including the Army, Air Force, Space Force, Navy, and U.S. Marine Corps.
This firm-fixed price contract totals up to $99.804 million over five years and streamlines the process for services to utilize the existing features of the Maven Smart System. Maven Smart System is part of the National Geospatial-Intelligence Agency&#8217;s Maven AI framework.
&#8220;To stay ahead of our adversaries, we must deliver software advantage at speed and at every level of the Department of Defense,&#8221; said Shannon Clark, Head of Defense Growth, Palantir.&nbsp;
Also Read:<a target="_blank" href="https://www.benzinga.com/news/24/09/40951997/palantir-co-founder-joe-lonsdale-backs-elon-musks-twitter-acquisition-saying-if-he-had-not-bought-it" rel="noreferrer noopener"> Palantir Co-Founder Joe Lonsdale Backs Elon Musk&#8217;s Twitter Acquisition, Saying If He Had Not Bought It Then &#8216;The Entire West Would Be At 10x The Threat&#8217;</a>
Under the latest development, Palantir&#8217;s platform will enhance AI-enabled battlespace awareness and support global integration, force management, logistics, and joint targeting workflows to improve military interoperability and readiness.
&#8220;This contract vehicle will allow every military department to tap into the innovation that the Office of Secretary of Defense and NGA have created through Maven to accelerate their own CJADC2 programs,&#8221; said Akash Jain, President of Palantir USG.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PLTR stock has gained over 149% in the past year. Investors can gain exposure to the stock via&nbsp;REX AI Equity Premium Income ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIPI#NASDAQ">AIPI</a>) and&nbsp;Global X Funds Global X Defense Tech ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHLD#NYSE">SHLD</a>).
Price Action: PLTR shares are trading lower by 2.39% to $35.95 premarket at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40946478/chinas-nio-says-40-of-its-store-managers-are-ex-tesla" target="_blank" rel="noreferrer noopener">China&#8217;s NIO Says 40% Of Its Store Managers Are Ex-Tesla</a></li>
</ul>

Equities

Contracts

Movers

AIPI

PLTR

SHLD

Palantir Wins Deal Worth Multi-Million Dollars To Expand Maven Smart System Across US Army, Air Force, Space Force & Navy

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) with a Outperform and raises the price target from $32 to $42.

EWTX

RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $42

NovaBay Pharmaceuticals shares are trading higher after the company announced it reached a definitive deal to sell its Avenova assets for $9.5 million.

B of A Securities analyst Benjamin Haynor maintains Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) with a Buy and lowers the price target from $31 to $19.

VSAT

B of A Securities Maintains Buy on Viasat, Lowers Price Target to $19

<ul>
<li>NVDA</li>
<li>LUNR</li>
<li>MADE</li>
<li>WAY</li>
<li>TSLA</li>
<li>DJT</li>
<li>FDX</li>
<li>LOT</li>
<li>QQQ</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

LUNR

MADE

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of September 20, 2024 (Via Swaggy Stocks)

On Wednesday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has urged a federal appeals court to overturn a $183 million judgment stemming from accusations of defrauding Medicaid.
The case, initiated in 2014, alleges that Eli Lilly underreported drug prices to Medicaid, resulting in smaller rebates owed to the program.
Last week,&nbsp;Walgreens Boots Alliance&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) agreed to pay $106.8 million to settle allegations that it submitted false claims to government healthcare programs, violating the False Claims Act&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40881893/walgreens-agrees-to-106-8m-settlement-over-alleged-false-billing-claims" rel="noreferrer noopener">and state regulations</a>.
The U.S. pharma giant claims it is being wrongfully held liable despite adhering to its interpretation of Medicaid&#8217;s complex rebate requirements.
The claims also highlight that Eli Lilly failed to disclose price increases billed to distributors, which were not reflected in its Medicaid pricing reports.
Reuters noted that Eli Lilly started reporting price increases after a 2017 rule change, though the company claims it had previously informed regulators about its pricing practices without facing any objections.
In 2022, a U.S. District Judge rejected Eli Lilly&#8217;s motion for summary judgment, ruling that its price statements were misleading and allowing the case to proceed. In May 2023, a jury found Eli Lilly responsible for $61 million in damages, which were tripled to $183 million under the federal False Claims Act.
Most recently, Oak Street Health, a subsidiary of&nbsp;CVS Health&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), agreed to settle for $60 million following allegations that it violated the <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40945496/cvs-subsidiary-oak-street-health-agrees-to-60m-settlement-in-medicare-kickback-violations" rel="noreferrer noopener">False Claims Act</a>.
The&nbsp;<a target="_blank" href="https://www.justice.gov/opa/pr/oak-street-health-agrees-pay-60m-resolve-alleged-false-claims-act-liability-paying-kickbacks" rel="noreferrer noopener">claims</a> involved paying kickbacks to third-party insurance agents to recruit seniors to its primary care clinics, a practice that led to false Medicare submissions.
The case has garnered attention from major business groups, including the U.S. Chamber of Commerce and Pharmaceutical Research and Manufacturers of America (PhRMA). These organizations argue that upholding the judgment would create uncertainty for regulated companies.
Price Action: LLY stock is trading higher by 1.45% to $928.28 premarket at the last check on Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40955083/holiday-opportunity-macys-plans-to-hire-31-500-seasonal-workers" target="_blank" rel="noreferrer noopener">Holiday Opportunity: Macy&#8217;s Plans To Hire 31,500 Seasonal Workers</a>.</li>
</ul>
Photo via Shutterstock

Legal

Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules

Wells Fargo analyst Colin Langan upgrades Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) from Equal-Weight to Overweight and raises the price target from $115 to $122.

Upgrades

Wells Fargo Upgrades Visteon to Overweight, Raises Price Target to $122

Guidance

RLND

RoyaLand Sees Prelim FY24 Adj. Net Loss $(1.059M)

Morgan Stanley analyst Andrew Ruben maintains MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) with a Overweight and raises the price target from $2175 to $2500.

MELI

Morgan Stanley Maintains Overweight on MercadoLibre, Raises Price Target to $2500

ZONE

CleanCore Solutions shares are trading higher. The company reported full-year fiscal 2024 results.

Wells Fargo analyst Colin Langan downgrades Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) from Equal-Weight to Underweight and lowers the price target from $13 to $9.

Downgrades

Wells Fargo Downgrades Dana to Underweight, Lowers Price Target to $9

Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) shares are trading higher after the company announced it signed a 20-year power purchase agreement with Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
The deal entails the launch of the Crane Clean Energy Center (CCEC) and the restart of Three Mile Island Unit 1, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40954951/constellation-to-launch-crane-clean-energy-center-restoring-jobs-and-carbon-free-power-to-the-grid" rel="noreferrer noopener">which was closed five years ago.</a>
As per this agreement, Microsoft will source energy from the renewed plant to align its PJM data centers&#8217; power use with carbon-free energy, supporting its sustainability goals.
Unit 1 is next to TMI Unit 2, which has been shut down since 1979 and is being decommissioned by Energy Solutions. Unit 1 operates independently and was unaffected by the accident.
Constellation will also seek a license renewal to extend operations until at least 2054. The CCEC is expected to be operational by 2028.
Joe Dominguez, president and, CEO, Constellation said, &#8220;Powering industries critical to our nation&#8217;s global economic and technological competitiveness, including data centers, requires an abundance of energy that is carbon-free and reliable every hour of every day, and nuclear plants are the only energy sources that can consistently deliver on that promise.&#8221;
Constellation purchased TMI Unit 1, in 1999 and was retired for economic reasons in 2019. The plant will be renamed the Crane Clean Energy Center in honor of&nbsp;Chris Crane, who was CEO of Constellation&#8217;s former parent company.
Bobby Hollis, VP of Energy, Microsoft said, &#8220;This agreement is a major milestone in Microsoft&#8217;s efforts to help decarbonize the grid in support of our commitment to become carbon negative. Microsoft continues to collaborate with energy providers to develop carbon-free energy sources to help meet the grids&#8217; capacity and reliability needs.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com//node/40909973" rel="noreferrer noopener">BlackRock, Microsoft, Others Team Up For $30B Artificial Intelligence Fund: Help US Fuel &#8216;AI Innovation And Economic Growth&#8217;</a>
U.S. Congressman Scott Perry said, &#8220;This critical step forward will ensure Pennsylvania has sufficient baseload power to meet its needs for decades to come while producing 3,400 jobs in our community.&#8221;
Investors can gain exposure to the stock via&nbsp;Strive Natural Resources and Security ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTWO#NYSE">FTWO</a>) and Virtus Reaves Utilities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTES#NYSE">UTES</a>).
Price Action: CEG shares are up 12.1% at $233.80 premarket at the last check Friday.
Photo by metamorworks via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40823561/this-under-the-radar-defensive-ai-sector-quietly-outperforms-all-others-despite-rec" target="_blank" rel="noreferrer noopener">This Under-The-Radar Defensive AI Sector Quietly Outperforms All Others, Despite Receiving &#8216;No Love&#8217; From Investors</a></li>
</ul>

FTWO

MSFT

UTES

Microsoft Taps Constellation For 20-Year Carbon-Free Power – 3,400 Jobs Coming To Pennsylvania

Morgan Stanley analyst Brian Harbour maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Overweight and raises the price target from $175 to $188.

Morgan Stanley Maintains Overweight on Darden Restaurants, Raises Price Target to $188

Wells Fargo analyst Colin Langan upgrades Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) from Equal-Weight to Overweight and raises the price target from $78 to $87.

APTV

Wells Fargo Upgrades Aptiv to Overweight, Raises Price Target to $87

September, True To Form

Forward S&P 500 Earnings Estimates Have Increased Sequentially 4 Weeks In A Row

Chart Of The Week: SPY - It's Not All Bad News (Technical Analysis)

This Is Just Normal Seasonal Jitters

S&P 500 - A Bullish And Bearish Analysis (Technical Analysis)

Why It Is A Bad Idea To Raise Tariffs

Volatility, Anyone?

S&P 500, Nasdaq 100 - Caution Following PPI, Technical Hurdles Ahead

Indices/Mag 10 Stocks Still Below All-Time Highs

Dividend Futures Before And After Fed Delivers 'Outsize' Rate Cut

ACTV

AFMC

AFSM

ANGL

ARKK

AVUV

BAPR

BBHY

BBMC

BFOR

BKHY

BKMC

BMVP

BOUT

BSJO

BSJP

BSJQ

BSJR

BSJS

BSJT

DDIV

DEUS

DFHY

DVLU

EQAL

ETHO

FALN

FDHY

FFSM

FFTY

FIBR

FLHY

FLQM

FMHI

FOVL

FRTY

FSCS

FSMD

FTDS

GBIL

GHYB

GHYG

GOOG

GOOGL

GOVT

GOVZ

GRPM

HAIL

HLGE

HOMZ

HYBB

HYDB

HYDW

HYGH

HYGV

HYLB

HYLS

HYMB

HYMU

HYUP

HYXF

HYXU

IBHD

IBHE

IBHF

IBHG

IHYF

IMCB

IMCG

IMCV

IVOG

IVOO

IVOV

JHMM

JPME

JSMD

KOMP

LGOV

LSAT

MAGS

MDYG

MDYV

MIDE

NAPR

NJAN

NUHY

NUMG

NUMV

ONEO

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

iShares Morningstar Mid-Cap Value ETF

Overview

iShares Morningstar Mid-Cap Value ETF (NASDAQ:IMCV), Quote.Headers.trade-ideas